Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1047Neoplasms 821Carcinoma, Non-Small-Cell Lung 806Prostatic Neoplasms 628Colorectal Neoplasms 536Lung Neoplasms 489Neoplasm Metastasis 439Multiple Myeloma 399Leukemia, Myeloid, Acute 392Ovarian Neoplasms 336Pancreatic Neoplasms 318Melanoma 300Squamous Cell Carcinoma of Head and Neck 269Recurrence 260Carcinoma, Hepatocellular 251Glioblastoma 241Brain Neoplasms 240Triple Negative Breast Neoplasms 214Head and Neck Neoplasms 211Carcinoma, Renal Cell 211Precursor Cell Lymphoblastic Leukemia-Lymphoma 205Lymphoma 203Stomach Neoplasms 200Endometrial Neoplasms 191Uterine Cervical Neoplasms 185Glioma 184Sarcoma 183Lymphoma, Non-Hodgkin 183Lymphoma, Large B-Cell, Diffuse 168Hematologic Neoplasms 165

Interventions

Magnetic Resonance Spectroscopy 116-fluoroestradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × HER2/Neu Negative × 90 days × Clear all
NCT02398773 2026-04-21

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

National Cancer Institute (NCI)

Phase 2 Active not recruiting
99 enrolled
Breast

HER2/Neu Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡